Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM

Business Wire11-22 06:31

Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology AUSTIN, Texas, November 21, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2485242400?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tmKkHF.uZkT96JHotxGVEg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ec2a810c00efaa321a853f4c9fa5ddd7","is_english":true,"pubTime":"2024-11-22 06:31","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2485242400","market":"us","top_or_hot":-1,"title":"Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM","media":"Business Wire","content":"<div>\n<p>Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology\nAUSTIN, Texas, November 21, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natera-announces-publication-over-100-223100613.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Natera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNatera Announces Publication of over 100 Peer-Reviewed Papers on SignateraTM\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-22 06:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/natera-announces-publication-over-100-223100613.html><strong>Business Wire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology\nAUSTIN, Texas, November 21, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global ...</p>\n\n<a href=\"https://finance.yahoo.com/news/natera-announces-publication-over-100-223100613.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2065171402.SGD","symbol_name":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","start_time":0,"source_url":"https://finance.yahoo.com/news/natera-announces-publication-over-100-223100613.html","article_id":"2485242400","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tmKkHF.uZkT96JHotxGVEg--~B/aD0yMDA7dz0yMDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/ec2a810c00efaa321a853f4c9fa5ddd7"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2485242400","pubTimestamp":1732228260,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology. AUSTIN, Texas, November 21, 2024----Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease  test, Signatera.Multiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date.In clinical studies, Signatera continues to demonstrate excellent performance, and evidence-based use of Signatera in a real-world setting exemplifies its clinical utility and potential in guiding clinical care. These impactful studies have not only paved the way for coverage across a broad range of cancer type","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","NTRA":"Natera, Inc.","LU2065731478.USD":"ALLSPRING (LUX) WORLDWIDE FUND - SMALL CAP INNOVA \"I\" (USD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","CLIA":"VERIDIEN CLIMATE ACTION ETF","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC"},"translate_title":"Natera宣布在SignateraTM上发表100多篇同行评审论文","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CLIA":1,"NTRA":1},"content_text":"Underscores the Company’s commitment to generating robust scientific evidence on its leading MRD technology\nAUSTIN, Texas, November 21, 2024--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it has surpassed a key milestone with over 100 peer-reviewed publications on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera.\nMultiple validation studies on Signatera have been published in top-tier journals like Nature, Nature Medicine, Nature Cancer, Journal of Clinical Oncology, Annals of Oncology, and JAMA Oncology. These include some of the largest and most comprehensive prospective studies of MRD testing to date.\nIn clinical studies, Signatera continues to demonstrate excellent performance, and evidence-based use of Signatera in a real-world setting exemplifies its clinical utility and potential in guiding clinical care. These impactful studies have not only paved the way for coverage across a broad range of cancer types and indications but have also led to increased adoption among the medical community.\n\"Natera has always had a focus on developing robust clinical evidence,\" said Alexey Aleshin, MD, chief medical officer and general manager of oncology. \"The ongoing delivery of high-quality data is critical to our mission as we work to positively impact cancer care for patients and their families. We want to thank our patients for participating in these studies and our collaborators for their partnership on these efforts.\"\nSignatera is the most widely used and extensively validated MRD test in the U.S., having helped more than 200,000 cancer patients. In addition to over 100 peer-reviewed publications, Natera has a deep pipeline that includes several phase III randomized clinical trials across colorectal, bladder, and breast cancer.\nAbout Signatera\nSignatera is a personalized, tumor-informed, molecular residual disease test for patients previously diagnosed with cancer. Custom-built for each individual, Signatera uses circulating tumor DNA to detect and quantify cancer left in the body, identify recurrence earlier than standard-of-care tools, and help optimize treatment decisions. The test is available for clinical and research use and is covered by Medicare for patients with colorectal cancer, breast cancer, ovarian cancer, and muscle-invasive bladder cancer, as well as for immunotherapy monitoring of any solid tumor. Signatera has been clinically validated across multiple cancer types and indications, with published evidence in over 100 peer-reviewed papers.\nAbout Natera\nNatera™ is a global leader in cell-free DNA and genetic testing, dedicated to oncology, women’s health, and organ health. We aim to make personalized genetic testing and diagnostics part of the standard of care to protect health and inform earlier, more targeted interventions that help lead to longer, healthier lives. Natera’s tests are validated by more than 250 peer-reviewed publications that demonstrate high accuracy. Natera operates ISO 13485-certified and CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, Texas, and San Carlos, California. For more information, visit www.natera.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20241121159633/en/\nContacts\nInvestor Relations: Mike Brophy, CFO, Natera, Inc., 510-826-2350, investor@natera.com Media: Lesley Bogdanow, VP of Corporate Communications, Natera, Inc., pr@natera.com","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2485242400"}